XML 48 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
Segment Information and Concentration of Business Risk (Tables)
 9 Months Ended
Sep. 30, 2015
Segment Information and Concentration of Business Risk [Abstract]  
Segment Information
The following is our segment information for the three and nine months ended September 30, 2015 (in thousands).

Three Months Ended September 30, 2015
Isis Core
 
Akcea Therapeutics
  
Elimination of Intercompany Activity
 
Total
 
      
Revenue:
     
Research and development
 
$
52,104
  
$
—
  
$
(3,186
)
 
$
48,918
 
Licensing and royalty
  
203
   
—
   
—
   
203
 
Total segment revenue
 
$
52,307
  
$
—
  
$
(3,186
)
 
$
49,121
 
Loss from operations
 
$
(37,183
)
 
$
(14,621
)
 
$
3,186
  
$
(48,618
)


Nine Months Ended September 30, 2015
Isis Core
 
Akcea Therapeutics
  
Elimination of Intercompany Activity
 
Total
 
      
Revenue:
     
Research and development
 
$
233,655
  
$
—
  
$
(3,186
)
 
$
230,469
 
Licensing and royalty
  
1,664
   
—
   
—
   
1,664
 
Total segment revenue
 
$
235,319
  
$
—
  
$
(3,186
)
 
$
232,133
 
Loss from operations
 
$
14,174
  
$
(30,661
)
 
$
3,186
  
$
(13,301
)

The following is our segment information for the three and nine months ended September 30, 2014 (in thousands) revised for comparative purposes to show operating costs for Akcea-related projects in 2014:

Three Months Ended September 30, 2014
Isis Core
 
Akcea Therapeutics
 
Total
 
    
Revenue:
   
Research and development
 
$
43,798
  
$
—
  
$
43,798
 
Licensing and royalty
  
265
   
—
   
265
 
Total segment revenue
 
$
44,063
  
$
—
  
$
44,063
 
Loss from operations
 
$
(14,886
)
 
$
(6,607
)
 
$
(21,493
)

Nine Months Ended September 30, 2014
Isis Core
 
Akcea Therapeutics
 
Total
 
    
Revenue:
   
Research and development
 
$
119,975
  
$
—
  
$
119,975
 
Licensing and royalty
  
9,325
   
—
   
9,325
 
Total segment revenue
 
$
129,300
  
$
—
  
$
129,300
 
Loss from operations
 
$
(41,609
)
 
$
(16,202
)
 
$
(57,811
)
Revenue from Significant Partners

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
Partner A
 
49 %
 
 
5 %
 
 
12 %
 
 
5 %
Partner B
 
37 %
 
 
72 %
 
 
32 %
 
 
59 %
Partner C
 
3 %
 
 
12 %
 
 
10 %
 
 
9 %
Partner D
 
2 %
  
0 %
  
 40 %
  
 0 %